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A series of recent reports has suggested PGC1a-driven upregulation of mitochondrial oxidative phosphory-
lation as a selective vulnerability of drug-resistant cancers. Accordingly, chemical inhibitors of respiration led
to selective eradication of such cancer cells due to their preferential sensitivity tomitochondrial production of
reactive oxygen species. These insights create a timely opportunity for a biomarker guided application of
already existing and newly emerging mitochondrial inhibitors in recurrent drug-resistant cancer, including
lymphomas, melanomas, and other malignant diseases marked by increased mitochondrial respiration.Therapy-Selected Quiescence
Current cancer therapeutics have extraordinary efficiency and
selectivity, often killing essentially 100% of malignant cells in a
culture dish at a dose where normal cells are spared. In vivo, it
appears that induction of cell death is never complete. Surviving
cells may no longer proliferate, but persist in a quiescent or slow-
cycling state for years. This phenotype may have either preex-
isted in a subset of cells from the heterogeneous tumor mass
(e.g., ‘‘cancer stem cells’’) or may have been acquired as a
consequence of the cytotoxic treatment. Either way, it is now
well established that the very same therapeutic regimen, whether
cytotoxic or ‘‘targeted,’’ can drive both apoptotic cell death and
selection of therapy resistant quiescent or slow-cycling cells, a
process I will refer to as therapy-selected quiescence (TSQ).
Cells undergoing TSQ may be thought of as ‘‘cancer memory
cells’’ that build a reservoir to fuel cancer recurrence (Figure 1A).
A well established form of TSQ is therapy-induced senes-
cence (TIS). Common therapies such as radiation and genotoxic
chemotherapy trigger either apoptosis or TIS, with the specific
response being determined by the dose. High doses cause cell
death, whereas lower doses induce TIS. The heterogeneity of
the tumor environment may lead to gradients in drug exposure
that enable the coexistence of both therapeutic responses.
Senescence is mediated and maintained by cyclin-dependent
kinase inhibitors—p16Ink4a (CDKN2A), p21WAF1,CIP1 (CDKN1A),
and p27KIP1 (CDKN1B)—that are induced downstream of tumor
suppressor pathways including p53- and RB1-related proteins
(Schmitt et al., 2002). However, TIS also occurs in the absence
of these tumor suppressor pathways because they are
frequently defective in cancer cells that undergo TIS (Ewald
et al., 2010). TIS may be a double-edged sword; on the upside,
cellular senescence constitutes a barrier against malignant pro-
gression; and on the downside, the long-term persistence of
senescent cancer cells carries liabilities associated with their
proinflammatory secretory phenotype (Coppe´ et al., 2010) and
risks such as their resistance to apoptosis, and their potential
for re-entering the cell cycle (Roberson et al., 2005). Melanomas
arising from nevi are good examples for escape of oncogene-
driven cells from senescence (Dhomen et al., 2009). A related
paradigm is slow-cycling stem-like cancer cells. Like TIS cells,788 Cancer Cell 26, December 8, 2014 ª2014 Elsevier Inc.slow-cycling cells are drug-resistant (Dean et al., 2005) and
can therefore be selected with various cytotoxic agents (as
described in Roesch et al., 2013 and sections below). Reactiva-
tion of therapy-selected quiescent tumor cells might therefore
contribute to a significant portion of relapses after therapy.
Eradicating cancer cells escaping drug-induced apoptosis by
entering a TSQ state would therefore appear an important goal in
cancer therapy. This ambition hardly meshes with our limited
knowledge of specific vulnerabilities of quiescent/slow-cycling
tumor cells that could be targeted for therapy. Several recent re-
ports have presented data that strongly suggest mitochondrial
respiration as a specific vulnerability of TSQ cells, which when
exploited should be synthetically lethal with established cyto-
toxic therapies (Corazao-Rozas et al., 2013; Do¨rr et al., 2013;
Haq et al., 2013; Roesch et al., 2013).
Increased Mitochondrial Activity in Quiescent/
Slow-Cycling Cancer Cells
As originally discovered by Otto Warburg, rapidly proliferating
cancer cells are typically marked by high rates of aerobic gly-
colysis, a metabolic change that is exploited today in positron
emission tomography (PET) imaging of tumors. This property is
a universal hallmark shared by all rapidly dividing eukaryotic cells
including single celled yeasts. Quiescent cells, in contrast,
appear to rely on complete oxidation of pyruvate to CO2 to
meet their ATP demands. Aerobic glycolysis, in addition to other
metabolic changes, may serve to optimally support the anabolic
requirements of proliferating cancer cells (Lunt and Vander Hei-
den, 2011;Ward and Thompson, 2012). It enables cancer cells to
divert glucose carbon from mitochondrial ATP production to the
synthesis of biomolecules needed for biomass accumulation
and cell division. In the simplest scenario, one might predict
that the metabolism of TSQ cells resembles that of resting
normal cells (i.e., high rate of mitochondrial respiration) rather
than that of the proliferating tumor cells from which they were
selected (anaerobic glycolysis). Recent studies have shown
that this is true, at least for some TSQ cells.
Lymphoma cells undergoing TIS were found to be metaboli-
cally hyperactive, a remarkable finding in light of their nonproli-
ferative state (Do¨rr et al., 2013). Em-myc lymphoma cells
A B Figure 1. Models of Therapy-Induced
Quiescence Leading to Upregulation of
Mitochondrial Respiration and Effect of
Mitochondrial Inhibitors
(A) Drug treatment leads to apoptotic cell death in
the bulk of the tumor mass. A minority of cells
escape into a quiescent/senescent state with
upregulated OXPHOS. When these cancer mem-
ory cells escape quiescence, they give rise to
relapse.
(B) Based on the reports summarized in this article,
drug treatment would select for slow-cycling
therapy-resistant cancer cells in which transcrip-
tional pathways are upregulated that induce ETC
proteins and OXPHOS. OXPHOS upregulation is
expected to selectively sensitize drug selected
cells to mitochondrial inhibitors (depicted in pur-
ple), resulting in ROS formation and downstream
events that cumulate in synthetic lethality of the
drug-resistant cancer.
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responded to treatment with cyclophosphamide or adriamycin
by uniformly undergoing TIS as indicated by decreased BrdU
incorporation and positivity for senescence-associated b-galac-
tosidase (Do¨rr et al., 2013). Consistent with their TIS phenotype,
these tumors are quiescent in vivo as shown by undetectable
signals in [18F]fluorothymidine PET. Unexpectedly, however,
these drug-treated TIS tumors exhibit a stronger signal than un-
treated tumors in [18F]fluorodeoxyglucose PET, indicating that
they have increased glucose uptake. In vitro, the Em-myc;BCL2
lymphoma cells also show increased glucose uptake and meta-
bolism to pyruvate and lactate. At first sight, it thus appears that
TIS reinforces the Warburg effect.
However, Em-myc;BCL2 lymphoma cells undergoing TIS also
showed several signs untypical of theWarburg effect: (1) they not
only accumulated lactate, but also citrate, indicating that TIS
cells also increased flux into the tricarboxylic acid (TCA) cycle;
(2) they upregulated isoform 1 of pyruvate kinase (PKM1), thus
providing abundant fuel for the TCA cycle; and (3) they activated
AMP-activated protein kinase (AMPK) signaling, suggesting that
their energy demand is greater than what can be met through
anaerobic glycolysis. All three findings indicated that unlike
with proliferating cancer cells, increased glucose utilization of
TIS cells drives the TCA cycle that feeds intomitochondrial respi-
ration. Consistent with this interpretation are the observations
that mitochondrial oxygen consumption rate and intracellular
ATP levels were strongly increased in Em-myc;BCL2 lymphoma
cells undergoing TIS. These cells display a hybrid form of energy
metabolism, marked by high levels of glucose utilization, mito-
chondrial respiration, and fatty acid oxidation, apparently geared
toward maximizing ATP production.
Similar upregulation of mitochondrial respiration was found in
drug selected slow-cycling cancer cells, which are required for
continuous maintenance of melanomas (Roesch et al., 2010).
JARID1B/KDM5B is a histone 3 K4 demethylase that is highly
expressed in benign nevi, which undergo oncogene-induced
senescence (Dhomen et al., 2009); but it is downregulated in pri-
mary andmetastatic melanomas (Roesch et al., 2005). Due to tu-
mor heterogeneity, a small portion of melanoma cells typically
retains JARID1B expression, however. Even subpopulations ofcultured melanoma cell lines switch to a JARID1Bhigh phenotype
in an apparently stochastic fashion (Gupta et al., 2011; Roesch
et al., 2010). These JARID1Bhigh cells cycle very slowly, but
have increased self-renewal capacity, stem cell-like properties,
and are required for melanoma maintenance in vitro and in vivo
(Roesch et al., 2010). Like TIS cells, slow-cycling JARID1Bhigh
cells are drug-resistant and can therefore be selected with
various cytotoxic agents (cisplatin, bortezomib, vemurafenib, te-
mozolomide, etc.) (Roesch et al., 2013). Proteomic profiling of
these cells revealed a striking upregulation of proteins involved
in mitochondrial respiration (OXPHOS), including subunits of
complexes I, III, IV, and ATP synthase (Roesch et al., 2013).
This resulted in increased oxygen consumption, increased mito-
chondrial ATP levels, and increased production of H2O2.
In summary, an unexpected common denominator of these
scenarios of therapy-selected quiescence is metabolic reprog-
ramming to upregulate OXPHOS genes and increase oxygen
consumption and ATP production (Do¨rr et al., 2013; Roesch
et al., 2013).
Increased Energy Demand of Cancer Cells Undergoing
Therapy-Induced Senescence
Why is the energy demand of seemingly quiescent cancer cells
so high that it cannot be met without upregulating mitochondrial
activity? It turns out that the TIS cells studied by Do¨rr et al. (2013)
have ramped up three highly energy consuming pathways: pro-
tein synthesis and folding, protein ubiquitylation, and proteaso-
mal degradation.
Various forms of senescence are known to coincide with the
so-called senescence-associated secretory phenotype (SASP),
a NFkB driven program to synthesize copious amounts of secre-
tory proteins (Chien et al., 2011; Coppe´ et al., 2010; Freund et al.,
2011). Increased protein synthesis and flux through the secretory
pathway put high demands on the protein folding capacity of
chaperones in the ER. When this capacity is exhausted, ER
stress will result, which leads to induction of the unfolded protein
response (UPR) (Cao and Kaufman, 2012; Walter and Ron,
2011). Em-myc;BCL2 lymphoma cells undergoing TIS show a
strong induction of the UPR. UPR signaling sets into motion a
program that directs either adaptation or cell death (Kim et al.,Cancer Cell 26, December 8, 2014 ª2014 Elsevier Inc. 789
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toward increasing the ER protein folding capacity through induc-
tion of chaperones and the removal of unfolded proteins by up-
regulating ER-associated degradation through the proteasome
and autophagy pathways. The apoptotic response, which may
be a consequence of sustained, irreparable ER stress, involves
several mitochondria-dependent and independent pathways
(Kim et al., 2008; Tabas and Ron, 2011). Of particular importance
are the UPR-induced transcription factors ATF4 and CHOP,
which stimulate protein synthesis, causing ATP depletion, oxida-
tive stress, and apoptotic cell death (Han et al., 2013).
Despite UPR activation and strong induction of ATF4 and
CHOP, Em-myc:BCL2 lymphoma cells in TIS do not undergo
apoptosis. This could be due to a combination of factors such
as overexpression of BCL2, induction of NFkB (as part of
SASP), and maintenance of high ATP levels due to upregulation
of glycolysis and OXPHOS. Instead of inducing apoptosis, UPR
signaling may reinforce or even drive the quiescent state of TIS
cells in the absence of functional p53 and RB1 tumor suppressor
pathways. For example, the UPR is known to suppress cyclin D1
synthesis via phosphorylation of eIF2a (Brewer et al., 1999).
Nevertheless, it is likely that TIS cells live on the edge with
respect to proapoptotic signaling.
Whether the increased OXPHOS occurring in drug-resistant
slow-cycling stem-like cancer cells (Roesch et al., 2013) sustains
a similar anabolic secretory program as found in TIS cells is
currently unknown, as is the status of UPR signaling in these
cells. It is noteworthy, however, that just like TIS cells, stem-
like cancer cells are known to display increased NFkB activity,
which could potentially drive a secretory program (Fulda, 2013).
How Is Mitochondrial Respiration Upregulated in
Response to Therapy?
Yet another recent example of drug-induced OXPHOS, again in
melanoma, has shed light on this important question. Upregula-
tion of OXPHOS genes and an increase in mitochondrial biogen-
esis and ATP levels was found to coincide with BRAF(V600E)
mutant melanomas acquiring resistance to BRAF inhibitors
(Haq et al., 2013). OXPHOS upregulation was found to occur
via microphthalmia-associated transcription factor (MITF), a me-
lanocyte-lineage transcription factor, and bona fide melanoma
oncogene (Garraway et al., 2005). MITF directly drives the
expression of proliferator-activated receptor g (PPARg) coacti-
vator-1a (PGC1a and PPARGC1A) (Figure 1B, a known master
regulator of mitochondrial biogenesis, see Scarpulla et al.,
2012). In fact, 10% of human melanomas overexpress MITF,
PGC1a, and OXPHOS genes and have increased respiration
evenwithout BRAF inhibitor treatment (Vazquez et al., 2013). Ge-
netic evidence demonstrates that such tumors depend on
PGC1a for survival and tumor progression. In addition, MITF/
PGC1a-dependent OXPHOS upregulation confers resistance
to cancer drugs whose mechanism-of-action involves apoptosis
induced by reactive oxygen species (ROS) (Vazquez et al., 2013).
It is tempting to speculate that TIS and slow-cycling stem-
like cancer cells also invoke PGC1a induction to upregulate
OXPHOS. For example, Em-myc lymphoma cells undergoing
TIS show phosphorylation of adenosine monophosphate
AMPK (Do¨rr et al., 2013), a known activator of PGC1a (Scarpulla
et al., 2012). However, not all melanomas resistant to BRAF inhi-790 Cancer Cell 26, December 8, 2014 ª2014 Elsevier Inc.bition upregulate OXPHOS via PGC1a (Corazao-Rozas et al.,
2013). The remaining tumors may utilize some of the other tran-
scriptional pathways known to regulate mitochondrial biogen-
esis, for example Nuclear Respiratory Factor 1, (NRF)2, and/or
MYC (Scarpulla et al., 2012). It is also noteworthy that the small
fraction of melanomas that are intrinsically resistant to BRAF in-
hibition (as opposed to acquiring resistance in response to BRAF
inhibition) are marked by low, rather than high, MITF expression
(Konieczkowski et al., 2014). Overall, the MITF-PGC1a interplay
is complex due to mutual feedforward regulation (Ronai, 2013).
Reliance on Mitochondrial Respiration as a Cancer
Selective Vulnerability
Exploiting the altered metabolism of cancer cells for therapy has
become a widely accepted concept (Schulze and Harris, 2012).
The studies discussed here strongly suggest that reliance on
OXPHOS may represent a previously unexpected ‘‘druggable’’
vulnerability of (multi)drug-resistant cancers. Minimally, this
would apply to lymphomas undergoing TIS in response to cyto-
toxic therapy (Do¨rr et al., 2013), to slow-cycling melanoma cells
selected for a JARID1Bhigh phenotype by cytotoxic agents
(Roesch et al., 2013), and to BRAF mutant melanomas escaping
therapy with BRAF inhibitors (Haq et al., 2013). These examples
make a strong case for inhibitors of OXPHOS to combat drug-
resistant cancer, especially melanomas and lymphomas.
Experimental support for this proposition is provided by the
antitumor activity of genetic ablation of OXPHOS components
in melanomas (Vazquez et al., 2013). In addition, various chem-
ical inhibitors of OXPHOS were able to overcome resistance to
widely used targeted and cytotoxic treatments (Table 1). Thus,
mitochondrial inhibitors proved effective for synthetic lethal tar-
geting of drug-resistant cancer cells marked by high OXPHOS
activity.
Whereas most of the mitochondrial inhibitors and decouplers
employed in the above studies have narrow therapeutic indices
and are for laboratory use only, there is a sizeable collection of
clinically used drugs that inhibit the electron transport chain
(ETC). These include, for example, tamoxifen and metformin,
which inhibit complex I; resveratrol, a complex III antagonist;
and the complex V inhibitor 3,3-diindolylmethane (reviewed in
Rohlena et al., 2011; Toogood, 2008). Metformin, in particular,
was found highly effective against stem-like cancer cells and
to synergize with chemotherapeutics in the mouse (Hirsch
et al., 2009; Iliopoulos et al., 2011). In addition, there are a num-
ber of emerging mitochondrial inhibitors that have been suc-
cessfully used in rodent tumor studies with manageable toxicity,
at least in the short term (Corazao-Rozas et al., 2013; Rico-Bau-
tista et al., 2013; Rohlena et al., 2011). These substances may
merit future development into clinical candidates.
Mechanism-of-Action of Mitochondrial Inhibitors as
Anticancer Agents
ATP levels may not be limiting for cancer cells (Scholnick et al.,
1973). To the contrary, some cancer cells engage various modes
of dissipating ATP levels in order to alleviate negative feedback
inhibition on glycolysis, a mechanism required for efficient flux
of glucose carbon into macromolecular synthesis pathways
(Fang et al., 2010; Vander Heiden et al., 2010). It is therefore un-
likely that the cytotoxicity of OXPHOS inhibitors in the described
Table 1. Synthetic Lethal Combinations of Mitochondrial Inhibitors with Established Cancer Treatments
Reference Cancer Mitochondrial Inhibitor Target Synthetically Lethal with
Roesch et al., 2013 melanoma rotenone complex I (NADH:ubiquinone
oxidoreductase)
cisplatin, in vitro
oligomycin complex V (F0/F1 ATPase) cisplatin, in vitro
phenformin complex I vemurafenib, in vivo
Haq et al., 2013 melanoma rotenone complex I vemurafenib, in vivo
TTFA (thenoyltrifluoroacetone) complex II (Succinate dehydrogenase) vemurafenib, in vivo
oligomycin complex V (F0/F1 ATPase) vemurafenib, in vivo
2,4-dinitrophenol mitochondrial uncoupler vemurafenib, in vivo
CCCP (carbonyl cyanide
m-chlorophenyl hydrazone)
mitochondrial uncoupler vemurafenib, in vivo
Do¨rr et al., 2013 lymphoma antimycin A complex III (ubiquinone-cytochrome c
oxidoreductase)
adriamycin, in vitro
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death appears to result from the deleterious effects of ROS.
Indeed, the proapoptotic activity of mitochondrial inhibitors
can be reversed by antioxidants (as described in Rico-Bautista
et al., 2013; Sundberg et al., 2009; Watabe and Nakaki, 2007),
suggesting that oxidative stress rather than ATP depletion is
the primary trigger of apoptosis in response to ETC inhibition.
At the same time, inhibition of ROS detoxifying systems such
as superoxide dismutase (SOD), glutathione, or thioredoxins
would seem to bear potential in combination with mitochondrial
inhibitors. Several inhibitors of ROS detoxification are under
development (Wondrak, 2009).
With regards to mechanism-of-action, it is well established
that inhibition of ETC complexes causes major leakage of elec-
trons and subsequent superoxide and hydrogen peroxide gener-
ation (reviewed in Rohlena et al., 2011). This is especially true for
cancer cells that have upregulated OXPHOS (Corazao-Rozas
et al., 2013; Vazquez et al., 2013). Although small increases in
ROS can be protumorigenic due to damage to macromolecules,
high levels of ROS induce apoptosis through various mecha-
nisms, including permeabilization of the outer mitochondrial
membrane and cytochrome C release (Madesh and Hajno´czky,
2001), as well as induction of the UPR (Rico-Bautista et al.,
2013) (Figure 1B), which is known to engage in a self-reinforcing
cycle with oxidative stress (Malhotra and Kaufman, 2007). This
‘‘threshold concept’’ of ROS activity and the preferential sensi-
tivity of cancer cells toward apoptosis induced by high levels
of ROS is now widely established and provides a solid basis
for cancer selectivity of mitochondrial inhibitors (reviewed in
Kong et al., 2000; Luo et al., 2009; Trachootham et al., 2009;
Watson, 2013; Wondrak, 2009).
Which Cancer Patients Might Benefit from
Mitochondrial Inhibitors?
If these concepts are well established in the basic science litera-
ture, why have mitochondrial inhibitors been slow in coming in
the clinic? A reasonmay be that it has been challenging to predict
which patients would benefit from such therapies. Several recent
clinical trials failed to show benefits. For example, the mitochon-
drial inhibitor elesclomol in combinationwith paclitaxel did not in-
crease progression-free survival in a phase III melanoma trial
(O’Day et al., 2013). Likewise, retrospective studies of the effectsof metformin, at antidiabetic doses, on prostate cancer mortality
have delivered contradictory results that dampened overall
enthusiasm (Azvolinsky, 2014). Although the effectiveness of
metformin is more appropriately tested in randomized prospec-
tive trials, which are now underway, even those may fail if per-
formed in an unselected patient cohort. Notably, the ‘‘flopped’’
elesclomol trial actually did reveal a statistically significant
improvement in median progression-free survival for the elesclo-
mol/paclitaxel combination in a subgroup of patients with
normal, as opposed to increased, levels of lactate dehydroge-
nase (O’Day et al., 2013). High levels of this metabolic enzyme,
which catalyzes the conversion of pyruvate to lactate, may stim-
ulate anaerobic glycolysis, thereby enabling escape from mito-
chondrial inhibition.
Considering the points above, clinical testing of mitochondrial
inhibitors stands to win as much from effective biomarkers as
any other form of new therapy. A main significance of the new
studies summarized in this article (Corazao-Rozas et al., 2013;
Do¨rr et al., 2013; Haq et al., 2013; Roesch et al., 2013; Vazquez
et al., 2013) may lie with their opening of a treasure trove of po-
tential biomarkers for patient stratification in future clinical trials
(Table 2). Chief among these would be OXPHOS components,
such as complex I–V subunits and oxidative stress defenders
such as hemeoxigenase 1, SOD, and catalase (CAT) genes,
which were repeatedly found upregulated in drug-resistant can-
cers. Upstream regulators of OXPHOS gene expression such as
PCG1a and NRF2 would also seem promising candidate bio-
markers. While nuclear accumulation of NRF2 mediates an
adaptive response to oxidative stress and is thus typically
thought of as an indicator of chemoresistance (Villeneuve
et al., 2010), recent evidence implicated the transcription factor
in a threshold-dependent feedforward loop of ROS generation
cumulating in cell death (Zucker et al., 2014). In addition, pros-
tate cancer cells with constitutively nuclear NRF2 are exquisitely
sensitive to the mitochondrial inhibitor SMIP004 (Rico-Bautista
et al., 2013). It is thus possible that high levels of nuclear NRF2
in advanced cancers correspond with sensitivity to inhibitors of
OXPHOS, although more detailed validation is required. AMPK
may also be a surrogate marker for energy stress in drug-resis-
tant cancer with increased mitochondrial activity (Do¨rr et al.,
2013). More classical indicators of redox and energy status,
such as the levels of reduced glutathione, ROS, and ATP, asCancer Cell 26, December 8, 2014 ª2014 Elsevier Inc. 791
Table 2. Potential Biomarkers to Identify Patients Benefitting from Mitochondrial Inhibitors
Type Potential Biomarkers Cancer Type Tested
Do¨rr et al., 2013
Proteins phosphorylated AMPK (phospho-AMPK)-T172 up in lymphoma cells undergoing TIS
M1 isoform of pyruvate kinase (PKM1) up in lymphoma cells undergoing TIS
activating transcription factor 4 (ATF4) up in lymphoma cells undergoing TIS
C/EBP-Homologous Protein (CHOP) up in lymphoma cells undergoing TIS
phosphorylated JUN N-terminal kinase
(phospho-JNK)-T183/185
up in lymphoma cells undergoing TIS
high molecular weight ubiquitin conjugates up in lymphoma cells undergoing TIS
sequestosome 1 (SQSTM1/p62) up in lymphoma cells undergoing TIS
microtubule-associated protein 1 light
chain 3 (MAP1-LC3) isoform II
up in lymphoma cells undergoing TIS
lysosomal vacuolar type ATPase (V-ATPase A1) up in lymphoma cells undergoing TIS
Metabolites citrate/glucose ratio up in lymphoma cells undergoing TIS
lactate/glucose ratio up in lymphoma cells undergoing TIS
pyruvate/glucose ratio up in lymphoma cells undergoing TIS
ATP up in lymphoma cells undergoing TIS
Haq et al., 2013
Organelle mitoTracker Green/Red (mitochondrial density) up in BRAF inhibitor treated melanoma cells
Proteins MITF up in BRAF inhibitor treated melanoma cells
peroxisome proliferator-activated receptor g
coactivator 1 (PPARGC1A/PGC-1a)
up in BRAF inhibitor treated melanoma cells
mRNAs MITF up in BRAF inhibitor treated melanoma cells
peroxisome proliferator-activated receptor g
coactivator 1 (PPARGC1A/PGC-1a)
up in BRAF inhibitor treated melanoma cells
succinate dehydrogenase (complex II) subunit B (SDHB) up in BRAF inhibitor treated melanoma cells
succinate dehydrogenase (complex II) subunit D
(SDHBSDHD)
up in BRAF inhibitor treated melanoma cells
mitochondrial F1 ATP synthase (complex V) beta
subunit (ATP5B)
up in BRAF inhibitor treated melanoma cells
mitochondrial F1 ATP synthase (complex V) delta
subunit (ATP5D)
up in BRAF inhibitor treated melanoma cells
mitochondrial F0 ATP synthase (complex V) subunit 9
(ATP5G1)
up in BRAF inhibitor treated melanoma cells
cytochrome C oxidase (complex IV) subunit 15 (COX15) up in BRAF inhibitor treated melanoma cells
CAT up in BRAF inhibitor treated melanoma cells
superoxide dismutase 2 (mitochondrial) (SOD2) up in BRAF inhibitor treated melanoma cells
Metabolite mitochondrial ROS (MitoSOX) up in BRAF inhibitor treated melanoma cells
Roesch et al., 2013
Proteins jumonji/ARID domain-containing demethylase (JARID1B) up in therapy selected melanoma cells
NADH:ubiquinone oxidoreductase (complex I) alpha
subcomplex subunit 4 (NDUFA4)
up in therapy selected melanoma cells
NADH:ubiquinone oxidoreductase (complex I) beta
subcomplex subunit 1 (NDUFB1)
up in therapy selected melanoma cells
ubiquinone-cytochrome c oxidoreductase (complex III)
subunit 7 (UQCRB)
up in therapy selected melanoma cells
cytochrome C oxidase (complex IV) subunit 7A2 (COX7A2) up in therapy selected melanoma cells
mitochondrial F0 ATP synthase (complex V) B chain
(ATP5F1)
up in therapy selected melanoma cells
mitochondrial F0 ATP synthase (complex V) subunit g
(mitochondrial ATP5L)
up in therapy selected melanoma cells
hexokinase 1 (HK1) down in therapy selected melanoma cells
(Continued on next page)
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Table 2. Continued
Type Potential Biomarkers Cancer Type Tested
Hexokinas 2 (HK2) down in therapy selected melanoma cells
Corazao-Rozas
et al., 2013
Protein CAT up in BRAF inhibitor treated melanoma cells
Metabolites ratio of oxidized/reduced glutathione (GSSG/GSH) up in BRAF inhibitor treated melanoma cells
Vazquez et al., 2013
mRNAs peroxisome proliferator-activated receptor g
coactivator 1 (PPARGC1A/PGC-1a)
up in PGC1a overexpressing melanoma cells
ERRa up in PGC1a overexpressing melanoma cells
isocitrate dehydrogenase 3 (NAD+) alpha (IDH3A) up in PGC1a overexpressing melanoma cells
NADH:ubiquinone oxidoreductase (complex I) 30 kDa
subunit (NDUFS3)
up in PGC1a overexpressing melanoma cells
cytochrome C oxidase (complex IV) subunit Va (COX5A) up in PGC1a overexpressing melanoma cells
mitochondrial F0 ATP synthase (complex V) subunit 9
(ATP5G1)
up in PGC1a overexpressing melanoma cells
cytochrome C (CYTC) up in PGC1a overexpressing melanoma cells
Proteins peroxisome proliferator-activated receptor g
coactivator 1 (PPARGC1A/PGC-1a)
up in PGC1a overexpressing melanoma cells
mitochondrially encoded cytochrome C oxidase I (MT-CO1) up in PGC1a overexpressing melanoma cells
mitochondrial F1 ATP synthase alpha subunit (ATP5A1) up in PGC1a overexpressing melanoma cells
ubiquinone-cytochrome c oxidoreductase (complex III)
core subunit 2 (UQCRC2)
up in PGC1a overexpressing melanoma cells
Metabolites Citrate down in melanoma cells engineered to downregulate
PGC1a
Aconitate down in melanoma cells engineered to downregulate
PGC1a
Isocitrate down in melanoma cells engineered to downregulate
PGC1a
Fumarate down in melanoma cells engineered to downregulate
PGC1a
Malate down in melanoma cells engineered to downregulate
PGC1a
ATP down in melanoma cells engineered to downregulate
PGC1a
Lactate up in melanoma cells engineered to downregulate PGC1a
dihydroxyacetone phosphate, DHAP up in melanoma cells engineered to downregulate PGC1a
ATP up in melanoma cells engineered to overexpress PGC1a
Lactate down in melanoma cells engineered to overexpress PGC1a
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these are less practical to measure, at least in fixed clinical ma-
terial.
It is anticipated that mitochondrial inhibitors could be used
either as second-line treatment of drug-resistant cancers or
even as first-line treatment in combination with standard-of-
care cytotoxic or targeted therapies (Figure 1B). Biomarker-
guided clinical trials will be necessary to rigorously assess these
options.
Potential Limitations
Despite these promises, some important unknowns remain that
will require further research to be resolved. For example, it is too
early to say how pervasive the switch to oxidative metabolism inTSQ cells is. Is it limited to the lymphoma and melanomamodels
discussed here, or is it a general characteristic of quiescent cells
as has been proposed (reviewed in Lunt and Vander Heiden,
2011; Ward and Thompson, 2012)? Once again, molecular
profiling—e.g., for the signatures outlined in Table 2—of other
cancer models and patient samples may assist in answering
this question. The important factor here is not necessarily the
actual fraction of drug-resistant cancers that show the respira-
tion phenotype, but rather the sensitivity and specificity with
which biomarkers can identify this fraction.
Likewise, the concept emerging from the observations sum-
marized here proposing that disruption of OXPHOS affords a
level of selectivity for cancer cells that is required for a successful
therapeutic approach has not yet been conclusively established.Cancer Cell 26, December 8, 2014 ª2014 Elsevier Inc. 793
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high demand of mitochondrial ATP such as cardiomyocytes or
with limited ability to withstand oxidative stress (cardiomyo-
cytes, dopaminergic neurons, etc.). Further research is required
to assess whether the selective upregulation of OXPHOS,
observed in drug-resistant cancers, creates enough of a thera-
peutic window to effectively and safely intervene with mitochon-
drial inhibitors. This being said, it should not be forgotten that
several mitochondrial inhibitors have been in safe clinical use
for decades. It is also worth noting that the toxicity associated
with mitochondrial inhibitors can be off-target effects. For
example, the neurotoxicity of rotenone and methyl-4-phenylpyr-
idinium is not a result of their activity in inhibiting complex I, but
rather to their off-target activity of disrupting microtubules (Choi
et al., 2011). Piericidin, another complex I inhibitor that does not
disrupt microtubules, is not neurotoxic. This example illustrates
that neurotoxicity is not an obligatory adverse effect of mito-
chondrial inhibitors.
As noted above, a main issue with agents such as metformin
and elesclomol in clinic trials has not been toxicity, but rather
lack of efficacy. These failures may indicate either ineffective se-
lection of patients most likely to benefit frommitochondrial inhib-
itors based on biomarkers or rapid development of resistance to
this therapeutic approach. It has been established for decades
that eukaryotic cells can be adapted to r0 cells, which lack mito-
chondrial DNA, demonstrating that respiration activity is not
strictly essential for survival, at least under nutrient rich condi-
tions. In addition, a recent study demonstrated that increased
glycolysis could compensate for inhibition of OXPHOS affected
by downregulating PGC1a in melanoma cells (Lim et al., 2014).
The escape was due to ROS-mediated stabilization of HIF1a,
which in turn upregulated glycolytic genes. Although it remains
to be seen whether pharmacological inhibition of OXPHOS
would lead to a similar adaptation, these findings suggest that,
as with many other cancer therapies, the real potential of mito-
chondrial inhibitors may lie with combining them with inhibitors
of other metabolic pathways such as glycolysis, glutamine utili-
zation, or ROS detoxification.
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Note Added in Proof
A recent report that appeared after peer review of this article further supported
the concept of mitochondrial inhibition as a modality in recurrent cancer:
Viale, A., Pettazzoni, P., Lyssiotis, C.A., Ying, H., Sa´nchez, N., Marchesini,
M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014). Oncogene abla-
tion-resistant pancreatic cancer cells depend on mitochondrial function.
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